Patupilone (Epothilone B)

For research use only.

Catalog No.S1364 Synonyms: EPO906

11 publications

Patupilone (Epothilone B) Chemical Structure

CAS No. 152044-54-7

Patupilone (EPO906, Epothilone B) is a paclitaxel-like microtubule-stabilizing agent with EC0.01 of 1.8 μM. Phase 2.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 250 In stock
USD 79 In stock
USD 99 In stock
USD 120 In stock
USD 210 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Patupilone (Epothilone B) has been cited by 11 publications

4 Customer Reviews

  • Matrigel invasion assay of H1299 cells treated with SDF-1α or SDF-1α plus Epothilone B prior to 0 or 2 Gy irradiation. After the treatment for 12 h, the H1299 cells that migrated to the bottom surface of the membrane were stained with Giemsa, and the number of migrated cells was calculated manually.

    Oncotarget, 2015, 6(13):10893-907.. Patupilone (Epothilone B) purchased from Selleck.

    Combination treatment with epothilone B and ABT-737 inhibited PI3K/AKT/mTOR pathway. SKOV-3 cells were treated with epothilone B (0.4 nM), ABT-737 (5 μM), or the combination, OVCAR-8 cells were treated with epothilone B (0.3 nM), ABT-737 (3 μM), or the combination, SGC-7901 were treated with epothilone B (0.4 nM), ABT-737 (5 μM), or the combination. Cells were exposed to compounds for 48 h, after which protein extracts were immunoblotted with specified antibodies for p-4E-BP-1, p-mTOR, p-AKT, caspase-3, PARP and β-actin.

    J Cancer Res Clin Oncol, 2016, 142(11):2281-9.. Patupilone (Epothilone B) purchased from Selleck.

  • Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Epothilone B for 48 h. Cell survival was measured by a standarad MTT assay.

     

     

    Dr. Helen Sadik of Johns Hopkins University. Patupilone (Epothilone B) purchased from Selleck.

    Combination treatment with epothilone B and ABT-737 inhibited PI3K/AKT/mTOR pathway. SKOV-3 cells were treated with epothilone B (0.4 nM), ABT-737 (5 μM), or the combination, OVCAR-8 cells were treated with epothilone B (0.3 nM), ABT-737 (3 μM), or the combination, SGC-7901 were treated with epothilone B (0.4 nM), ABT-737 (5 μM), or the combination. Cells were exposed to compounds for 48 h, after which protein extracts were immunoblotted with specified antibodies for p-4E-BP-1, p-mTOR, p-AKT, caspase-3, PARP and β-actin.

    J Cancer Res Clin Oncol, 2016, 142(11):2281-9. Patupilone (Epothilone B) purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Patupilone (EPO906, Epothilone B) is a paclitaxel-like microtubule-stabilizing agent with EC0.01 of 1.8 μM. Phase 2.
Targets
Tubulin [1]
(Cell-free assay)
1.8 μM(EC0.01)
In vitro

Epothilone B shows better activity than Epothilone A. The EC0.01 of Epothilone B is 1.8 μM. Epothilone B potently inhibits cell proliferation in HCT116 cells, with IC50 of 0.8 nM. [1] Epothilone B induces mitotic arrest and displays cytotoxicity in KB3-1, KBV-1, Hela, and Hs578T cells, with IC50 of 3 nM to 92 nM. Epothilone B competes with Taxol in binding to microtubules, with IC50 of 3.3 μM. [2] In MCF-7 cells overexpressing GFP-α-tubulin, Epothilone B (3.5 nM) efficiently blocks microtubule dynamics. Meanwhile, Epothilone B induces mitotic arrest with IC50 of 3.5 nM. [3] In multiple myeloma (MM) cells, including RPMI 8226, U266, MM.1S, LR5, and MR20, Epothilone B directly suppresses proliferation with IC50 of 1 nM to 10 nM. Similarly, Epothilone B (10 nM) also induces cell cycle arrest and apoptosis. [4] A recent study reveals that, in ovarian cancer Hey cells, Epothilone B (5 nM–100 nM) enhances surface epithelial cell adhesion antigen (EpCAM), without affecting the transcription or the total cellular level of EpCAM. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human LC-2-ad cell M{HhS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkK0TY5pcWKrdHnvckBw\iCqdX3hckBNSy1{LXHkJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{44P2VvME[g{txO NVLDe3F7W0GQR1XS
human A431 cell MmL2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4K0UGlvcGmkaYTpc44hd2ZiaIXtZY4hSTR|MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUmuPFZmNTB4IN88US=> NFT2OXpUSU6JRWK=
human SW1710 cell NXGxbVM1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MX7Jcohq[mm2aX;uJI9nKGi3bXHuJHNYOTdzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuNVRmNTB3IN88US=> NGDBeFNUSU6JRWK=
human Daoy cell M321e2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkOyTY5pcWKrdHnvckBw\iCqdX3hckBF[W:7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYpvwKwhUUN3ME2yMlc{\S1yNTFOwG0> NFzudWdUSU6JRWK=
human BFTC-905 cell M365RWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NELkcpNKdmirYnn0bY9vKG:oIHj1cYFvKEKIVFOtPVA2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC57OXWtNFUh|ryP MlHXV2FPT0WU
human A375 cell M2TnVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUjJcohq[mm2aX;uJI9nKGi3bXHuJGE{PzViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13ZT2wOUDPxE1? M4HMc3NCVkeHUh?=
human RKO cell NETyPWpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXj5TINiUW6qaXLpeIlwdiCxZjDoeY1idiCUS1:gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlQ4\S1yNTFOwG0> MUHTRW5ITVJ?
human KYSE-510 cell NWXvfHFtT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mnq2TY5pcWKrdHnvckBw\iCqdX3hckBMYVOHLUWxNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvOzinLUC1JO69VQ>? NYLmRpJXW0GQR1XS
human HLE cell NHqxdZRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXrJcohq[mm2aX;uJI9nKGi3bXHuJGhNTSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRThwMk\lMVA2KM7:TR?= NIO4NWlUSU6JRWK=
human MCF7 cell NEO2XphIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWjIOJJSUW6qaXLpeIlwdiCxZjDoeY1idiCPQ1[3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PE43PmVvMEWg{txO NHnmT|BUSU6JRWK=
human 786-0 cell MoLKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MoPrTY5pcWKrdHnvckBw\iCqdX3hckA4QDZvMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVEhdk1? MonIV2FPT0WU
human TE-8 cell MmLBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NF\yN4lKdmirYnn0bY9vKG:oIHj1cYFvKFSHLUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEyOSCwTR?= MYXTRW5ITVJ?
ovarian carcinoma 1A9 cell MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEPlOlZKdmirYnn0c5J6KGOxbnPlcpRz[XSrb36gZYdicW6|dDDveoFzcWGwIHPhdoNqdm:vYTCxRVkh[2WubDDndo94fGh? MU[xOlE{PDl{OB?=
human PANC-03-27 cell M2LmU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUTJcohq[mm2aX;uJI9nKGi3bXHuJHBCVkNvMEOtNlch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF|MjFOwG0> MoTkV2FPT0WU
human VMRC-RCZ cell NICwdmpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVTHe3V4UW6qaXLpeIlwdiCxZjDoeY1idiCYTWLDMXJEYiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUO2JO69VQ>? M{LjN3NCVkeHUh?=
human IGROV-1 cell MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MULJcohq[mm2aX;uJI9nKGi3bXHuJGlIWk:YLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE2PiEQvF2= M3;RenNCVkeHUh?=
human MG-63 cell NVvldnI{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXnOV2c6UW6qaXLpeIlwdiCxZjDoeY1idiCPRz22N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTZ3IN88US=> NIHLcYNUSU6JRWK=
human SIG-M5 cell NVXYUmtsT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHjsXG5KdmirYnn0bY9vKG:oIHj1cYFvKFOLRz3NOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTZ7IN88US=> MnLlV2FPT0WU
human NCI-H650 cell MnXLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEHs[IVKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOlUxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zNzFOwG0> MYHTRW5ITVJ?
human PSN1 cell MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVvpO3pJUW6qaXLpeIlwdiCxZjDoeY1idiCSU16xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yPzNizszN NY[2WIJEW0GQR1XS
human PA-1 cell MkXFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2fhbGlvcGmkaYTpc44hd2ZiaIXtZY4hWEFvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVc1KM7:TR?= NIPyPIFUSU6JRWK=
KB-8511 cells NULYT2VOT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVW3NkBp NFfLcldEd26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSgeIhmKGe{b4f0bEBw\iCyYXPsbZRigGWuLYLld4l{fGGwdDDoeY1idiCncHnk[ZJud2mmIHPhdoNqdm:vYTDj[YxteyCNQj24OVEyKGK7IEWwJJBmemOnboSgLFczKGi{IHX4dI9{fXKnKTygTWM2OD1yLkG4JO69VQ>? MVKxNVE{OzB6Nh?=
KB-31 cells NWPYV5hPT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{flPFczKGh? NVPRRXdsS2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JJRp\SCpcn;3eIghd2ZicHHjcIl1[XinbD3z[Y5{cXSrdnWgbJVu[W5iZYDp[IVzdW:rZDDjZZJkcW6xbXGgZ4VtdHNiS1KtN|Eh[nliNUCgdIVz[2WwdDCoO|IhcHJiZYjwc5N2emVr M2LKW|EyOTN|MEi2
human BHY cell M4fh[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXvLZ495UW6qaXLpeIlwdiCxZjDoeY1idiCESGmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE6PSCwTR?= NF3aPFBUSU6JRWK=
human BB30-HNC cell MnfQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M17HOmlvcGmkaYTpc44hd2ZiaIXtZY4hSkJ|MD3IUmMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJyMTFOwG0> MUPTRW5ITVJ?
human HOS cell MmTBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVS3RoRxUW6qaXLpeIlwdiCxZjDoeY1idiCKT2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlIyPSEQvF2= M3;ZUXNCVkeHUh?=
human 639-V cell NV;wS4NpT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkS1TY5pcWKrdHnvckBw\iCqdX3hckA3OzlvVjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlE5KM7:TR?= MUXTRW5ITVJ?
human ES1 cell  NYe0XJR4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFfJZYJKdmirYnn0bY9vKG:oIHj1cYFvKEWVMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlIyKM7:TR?= M3roV3NCVkeHUh?=
human TE-15 cell  NGDJeXRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{[wb2lvcGmkaYTpc44hd2ZiaIXtZY4hXEVvMUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlIzPSEQvF2= NIHPcmNUSU6JRWK=
human LXF-289 cell NHvkZXNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXrJcohq[mm2aX;uJI9nKGi3bXHuJGxZTi1{OEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI4PyEQvF2= NFjKU3FUSU6JRWK=
human CAL-12T cell NFr0eHVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYTJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC1zMmSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI{QSEQvF2= NVPsc|dtW0GQR1XS
human T84 cell MojXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXnJcohq[mm2aX;uJI9nKGi3bXHuJHQ5PCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMkSg{txO M3zBUnNCVkeHUh?=
human KYSE-450 cell MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGL0O4JKdmirYnn0bY9vKG:oIHj1cYFvKEu\U1WtOFUxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5{Nkeg{txO MVPTRW5ITVJ?
human LCLC-103H cell NEXiOldIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVfRb3k6UW6qaXLpeIlwdiCxZjDoeY1idiCOQ1zDMVExO0hiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkOxJI5O Ml:xV2FPT0WU
human NCI-H810 cell M2TmbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVPwNGZWUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFgyOCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwM{KyJO69VQ>? Mlr5V2FPT0WU
human HUTU-80 cell MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3viW2lvcGmkaYTpc44hd2ZiaIXtZY4hUFWWVT24NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzJ6IN88US=> NIjM[nNUSU6JRWK=
human NCI-H460 cell NUHQUlNFT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3rkU2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi0OlAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN|MzFOwG0> NFH6[phUSU6JRWK=
human HGC-27 cell MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUHoWmpTUW6qaXLpeIlwdiCxZjDoeY1idiCKR1OtNlch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN|ODFOwG0> NEPRcYNUSU6JRWK=
human HSC-2 cell NEHn[phIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXfJcohq[mm2aX;uJI9nKGi3bXHuJGhUSy1{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6zOlMhdk1? NX;XNZVJW0GQR1XS
human IA-LM cell MknuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmS4TY5pcWKrdHnvckBw\iCqdX3hckBKSS2OTTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|k{KM7:TR?= M1fES3NCVkeHUh?=
human HMV-II cell NWfud4VrT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3j2bmlvcGmkaYTpc44hd2ZiaIXtZY4hUE2YLVnJJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{QTRizszN NGH4U3FUSU6JRWK=
human COLO-679 cell M1zjT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Ml[1TY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLU[3PUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzl2IN88US=> MYfTRW5ITVJ?
human NCI-H2122 cell M1juXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWjXdWY3UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIyOjJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkSxJO69VQ>? NIGybWFUSU6JRWK=
human CAL-39 cell MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYjOVlJjUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytN|kh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjRzMTFOwG0> NYDORmtSW0GQR1XS
human SW954 cell NWXxZ3V6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYDJcpJ[UW6qaXLpeIlwdiCxZjDoeY1idiCVV{m1OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPDN4IN88US=> MW\TRW5ITVJ?
human LCLC-97TM1 cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3TtS2lvcGmkaYTpc44hd2ZiaIXtZY4hVEOOQz25O3ROOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwNES0JO69VQ>? NWH1XGZ2W0GQR1XS
human KYSE-270 cell MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MojBTY5pcWKrdHnvckBw\iCqdX3hckBMYVOHLUK3NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPDR3IN88US=> MUnTRW5ITVJ?
human NB13 cell NHrtNoJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1:1PWlvcGmkaYTpc44hd2ZiaIXtZY4hVkJzMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOFQ4KM7:TR?= MUDTRW5ITVJ?
human SK-LMS-1 cell NH3YO4pIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2jFS2lvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTF3TMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjZ2NjFOwG0> NWSzTVl7W0GQR1XS
human SW620 cell MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGXac|lKdmirYnn0bY9vKG:oIHj1cYFvKFOZNkKwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE43PDhizszN NUexTYFZW0GQR1XS
human HCT-15 cell NUfTR|RpT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mn\qTY5pcWKrdHnvckBw\iCqdX3hckBJS1RvMUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlcyPyEQvF2= NIrxUVJUSU6JRWK=
human DU-145 cell MoXiS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWrhU2dEUW6qaXLpeIlwdiCxZjDoeY1idiCGVT2xOFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjd{MTFOwG0> NWjUc3FEW0GQR1XS
human ST486 cell MnXoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn74TY5pcWKrdHnvckBw\iCqdX3hckBUXDR6NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuO|IyKM7:TR?= MV3TRW5ITVJ?
human A427 cell NVO2SldvT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYTJcohq[mm2aX;uJI9nKGi3bXHuJGE1OjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkiyPEDPxE1? MWLTRW5ITVJ?
human HT-1080 cell MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoTRTY5pcWKrdHnvckBw\iCqdX3hckBJXC1zMEiwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE45PDJizszN NILmRpNUSU6JRWK=
human NCI-H2009 cell Mk\VS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYOycI9pUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIxODliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLki2NkDPxE1? NF:4TplUSU6JRWK=
human SK-LU-1 cell NF3lclNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkHwTY5pcWKrdHnvckBw\iCqdX3hckBUUy2OVT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE45PjZizszN NWj0cHQ3W0GQR1XS
human SCC-4 cell MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnroTY5pcWKrdHnvckBw\iCqdX3hckBUS0NvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPFc4KM7:TR?= NWT5SYZ2W0GQR1XS
human NCI-H1299 cell NWfzSFJ5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M13DemlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixNlk6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC56ODFOwG0> M4[5VHNCVkeHUh?=
human NH-12 cell NFm4fXNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVfDWpZ3UW6qaXLpeIlwdiCxZjDoeY1idiCQSD2xNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQDlzIN88US=> MXXTRW5ITVJ?
human SK-UT-1 cell M1mwR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NY\UR3cyUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3VWE0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC56OUKg{txO M1zYTHNCVkeHUh?=
human Bel7402 Mln0VJJwdGmoZYLheIlwdiCjc4PhfS=> MmT3O|IhcA>? MoCwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCEZXy3OFAzKGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIhT2yxIHHzd4F6NCCLQ{WwQVAvQSEQvF2= NIW5e|QzOjN{MEO1OC=>
human A388 cell NWKzSYl6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnjHTY5pcWKrdHnvckBw\iCqdX3hckBCOzh6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD65OEDPxE1? M1judHNCVkeHUh?=
human SW982 cell MoHlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1z2PGlvcGmkaYTpc44hd2ZiaIXtZY4hW1d7OEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlk6QSEQvF2= NFfPfpdUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo In a mouse xenograft model of RPMI 8226 cells, Epothilone B (2.5 mg/kg–4 mg/kg) prolongs survival and suppresses tumor growth. [4] Similarly, in mouse xenograft models of prostate cancer cells, including DU145 and PC3, Epothilone B at the same dose also inhibits tumor growth. [6]

Protocol

Kinase Assay:[1]
- Collapse

Tubulin polymerization assay:

Calf brain microtubule proteins (MTP) are purified, which includes approximately 15%–20% microtubule associated proteins. The buffer (MES buffer) used for the Epothilone B-microtubule studies contains 0.1 M 2-morpholinoethanesulfonic acid (MES), 1 mM EGTA, 0.5 mM MgCl2, and 3 M glycerol at pH 6.6. Samples for electron microscopy are placed on carbon-over-Parlodion-coated grids (300 mesh) and negatively stained with 2% uranyl acetate. Microtubule assembly in the presence or absence of Epothilone B is monitored spectrophotometrically by using a spectrophotometer equipped with a thermostatically regulated liquid circulator. The temperature is held at 35 °C and changes in turbidity (representative of polymer mass) are monitored at 350 nm. Effective concentration (EC0.01), defined as the interpolated concentration capable of inducing an initial slope of 0.01 OD/min rate, is calculated using the formula EC0.01 = concentration/slope and expressed as the mean with standard deviation obtained from three different concentrations.
Cell Research:[2]
- Collapse
  • Cell lines: KB3-1, KBV-1, Hela, and Hs578T cells
  • Concentrations: 0–1 μM
  • Incubation Time: 72 hours
  • Method: For mitotic block and aberrant mitosis, cells are plated either in 48-well plates (for trypan blue and cell counting) or onto coverslips. After 24 hours, cells are treated with Epothilone B and scored at regular intervals. For the cytotoxicity analysis, cells are counted and scored as trypan blue positive or negative. Concurrently, coverslips andaliquots of cells in the culture supernatant are fixed and stained with Hoechst33342 in PBS. These cells are scored for cells blocked at the G2/M transition and aberrant mitosis.
    (Only for Reference)
Animal Research:[4]
- Collapse
  • Animal Models: Mice xenograft model of RPMI 8226 cells
  • Dosages: 2.5 mg/kg–4 mg/kg
  • Administration: Inject intravenously
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 102 mg/mL (200.91 mM)
Ethanol 102 mg/mL (200.91 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
5 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 507.68
Formula

C27H41NO6S

CAS No. 152044-54-7
Storage powder
in solvent
Synonyms EPO906
Smiles CC1CCCC2(C(O2)CC(OC(=O)CC(C(C(=O)C(C1O)C)(C)C)O)C(=CC3=CSC(=N3)C)C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00496600 Completed Drug: Patupilone|Drug: RAD001 Refractory Malignancy University of Medicine and Dentistry of New Jersey|Novartis Pharmaceuticals|National Cancer Institute (NCI)|Rutgers The State University of New Jersey July 2007 Phase 1
NCT00442741 Withdrawn Drug: Patupilone|Drug: Patupilone + Omeprazole Solid Tumors Novartis Pharmaceuticals|Novartis July 2007 Phase 1
NCT00468260 Terminated Drug: Patupilone Advanced Malignancies Novartis Pharmaceuticals|Novartis May 2007 Phase 1
NCT00448396 Completed Drug: Patupilone Advanced Malignancies Novartis Pharmaceuticals|Novartis March 2007 Phase 1
NCT00426140 Completed Drug: Patupilone Advanced Malignancies|Solid Tumors Novartis Pharmaceuticals|Novartis August 2006 Phase 1
NCT00426582 Completed Drug: Patupilone Advanced Solid Tumors Novartis Pharmaceuticals|Novartis August 2006 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Patupilone (Epothilone B) | Patupilone (Epothilone B) supplier | purchase Patupilone (Epothilone B) | Patupilone (Epothilone B) cost | Patupilone (Epothilone B) manufacturer | order Patupilone (Epothilone B) | Patupilone (Epothilone B) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID